Physician profile
John M Whapham
NPI 1154347011
$2,306.13
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,391 · 2020: $525 · 2021: $215 · 2022: $95.98 · 2023: $79.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $79.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $79.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $801.54 | 2019-2022 | |
| Medtronic USA, INC. | $343.61 | 2019 | |
| Depuy Synthes Sales INC. | $323.55 | 2019-2023 | Cerebase, Embotrap, N/A |
| Amgen INC. | $195.83 | 2019-2020 | |
| Penumbra, INC. | $136.26 | 2019 | |
| Microvention, INC. | $113.24 | 2019-2020 | |
| Ucb, INC. | $87.33 | 2019-2023 | Nayzilam |
| Emd Serono, INC. | $68.67 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $42.46 | 2019-2020 | |
| Sk Life Science, INC. | $36.69 | 2020 | |
| Neurelis, INC. | $34.17 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $22.02 | 2020 | |
| Lilly USA, LLC | $18.23 | 2019 | |
| Boston Scientific Corporation | $17.54 | 2019 | |
| Medtronic Vascular, INC. | $14.99 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13.52 | 2019 | |
| Celgene Corporation | $13.10 | 2020 | |
| Zimmer Biomet Holdings, INC. | $11.73 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Whapham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.